Literature DB >> 2216463

Expression of P0- and P3-RNA from the normal and translocated c-myc allele in Burkitt's lymphoma cells.

D Eick1, A Polack, E Kofler, G M Lenoir, A B Rickinson, G W Bornkamm.   

Abstract

We have studied the allele specific expression of c-myc P0- and P3-RNA in Burkitt's lymphoma (BL) cells. The steady state levels of P0-RNA show considerable variations in BL cells. Expression of P0-RNA was found to be restricted to the translocated allele, but could be induced by TPA from the normal allele. P0-transcription was particularly sensitive to inhibitors of protein synthesis compared to expression of P1-, P2- and P3-RNA. Transcription of P3-RNA is initiated in the first intron of the c-myc gene and has previously been described to be specific for translocated c-myc alleles in BL cells broken within exon 1 or intron 1. Here we show that P3-RNA is also expressed from an unrearranged c-myc gene. In the BL cell line Raji, substantial amounts of c-myc RNA are derived from the P3-promoter of the normal allele. This indicates that repression of the normal allele in BL cells does not include the P3-promoter. The potential coding capacity of P3-RNA is discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2216463

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  A novel mode for transcription inhibition mediated by PNA-induced R-loops with a model in vitro system.

Authors:  Alicia D D'Souza; Boris P Belotserkovskii; Philip C Hanawalt
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2018-01-31       Impact factor: 4.490

2.  Selection for c-myc integration sites in polyclonal T-cell lymphomas.

Authors:  Dana R Broussard; Jennifer A Mertz; M Lozano; Jaquelin P Dudley
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  RNA diversity has profound effects on the translation of neuronal nitric oxide synthase.

Authors:  Y Wang; D C Newton; G B Robb; C L Kau; T L Miller; A H Cheung; A V Hall; S VanDamme; J N Wilcox; P A Marsden
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

4.  Sequences in the human c-myc P2 promoter affect the elongation and premature termination of transcripts initiated from the upstream P1 promoter.

Authors:  T Meulia; A Krumm; C Spencer; M Groudine
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

5.  Molecular and cytological features of the mouse B-cell lymphoma line iMycEmu-1.

Authors:  Seong Su Han; Arthur L Shaffer; Liangping Peng; Seung Tae Chung; Jae Hwan Lim; Sungho Maeng; Joong Su Kim; Nicole McNeil; Thomas Ried; Louis M Staudt; Siegfried Janz
Journal:  Mol Cancer       Date:  2005-11-09       Impact factor: 27.401

6.  Small molecule inhibitors of IRES-mediated translation.

Authors:  Christos Vaklavas; Zheng Meng; Hyoungsoo Choi; William E Grizzle; Kurt R Zinn; Scott W Blume
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

7.  Transcription of human c-myc in permeabilized nuclei is associated with formation of Z-DNA in three discrete regions of the gene.

Authors:  B Wittig; S Wölfl; T Dorbic; W Vahrson; A Rich
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

8.  Hold back of RNA polymerase II at the transcription start site mediates down-regulation of c-myc in vivo.

Authors:  L J Strobl; D Eick
Journal:  EMBO J       Date:  1992-09       Impact factor: 11.598

9.  Hepatocyte growth factor-stimulated renal tubular mitogenesis: effects on expression of c-myc, c-fos, c-met, VEGF and the VHL tumour-suppressor and related genes.

Authors:  S C Clifford; K Czapla; F M Richards; D J O'Donoghue; E R Maher
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

10.  Transcriptional down-regulation of c-myc in human prostate carcinoma cells by the synthetic androgen mibolerone.

Authors:  D A Wolf; F Kohlhuber; P Schulz; F Fittler; D Eick
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.